Skip to main content
Delfa

← All assets

Rosiglitazone

14 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

14

Ongoing

0

Recruiting

0

Completed

9

Sites

507

Countries

42

Endpoints

327

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 327 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
4
Phase 2
5
Phase 3
4
Not applicable
1

Trials by status

Completed
9
Terminated
3
Withdrawn
1
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)
98
Safety / tolerability / PK
87
Global cognition
69
Caregiver / quality of life
22
Behavior / neuropsychiatric
20
Function / daily living
12
Memory
7
Neuroimaging
6
Other clinical outcomes
6

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 81 of 327 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

37

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

18

Mini-Mental State Examination (MMSE)Cognition

14

Neuropsychiatric Inventory (NPI)Behavior

12

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

14 of 14

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00490568Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

Rosiglitazone

Alzheimer’s disease

Age 51-91Ph 3Terminated272Jun 20091results
REFLECT-2Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

Donepezil, Rosiglitazone

Alzheimer’s disease

mild-to-moderate ADNot applicableCompleted249Jan 20091results
REFLECT-3Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

Rosiglitazone

Alzheimer’s disease

mild-to-moderate ADPh 3Completed194Mar 20091results
NCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

Rosiglitazone

Alzheimer’s disease

Alzheimer's diseasePh 3Completed138Sep 20081results
NCT00550420Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

Rosiglitazone

Alzheimer’s disease

Study partner/caregiver requiredPh 3Terminated70Feb 20091results
NCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

Rosiglitazone

Alzheimer’s disease

MMSE 16-26Ph 2Completed15Jul 20081results
NCT00381238Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

Rosiglitazone

Alzheimer’s disease

Study partner/caregiver requiredPh 2Completed7Feb 2009-results
RECALLRosiglitazone Effects on Cognition for Adults in Later Life

Rosiglitazone

MCI / preclinical Alzheimer’s

Age ≥55Ph 2Unknown3Dec 20115
Rosi XRQTc Study of Rosi XR in Healthy Volunteers

Rosiglitazone

Alzheimer’s disease

Age 18-45Ph 1Withdrawn2Aug 2009-
NCT00334568Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

Rosiglitazone

Alzheimer’s disease

MMSE 16-26Ph 2Terminated1Jul 2007-
Rosi XRPK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers

Rosiglitazone

Alzheimer’s disease

Healthy volunteersPh 1Completed1Nov 2008-
NCT00468897A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.

Rosiglitazone

Alzheimer’s disease

Age 18-55Ph 1Completed1May 2007-
NCT00688207Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

Rosiglitazone

Alzheimer’s disease

Alzheimer's diseasePh 1Completed1Sep 2008-
NCT00018382Insulin, Neurogenetics and Memory in Alzheimer's Disease

Rosiglitazone

Alzheimer’s disease

Age 55-80Ph 2Completed1Mar 2003-

Showing 1-14 of 14 trials